Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04346589
Recruitment Status : Recruiting
First Posted : April 15, 2020
Last Update Posted : June 9, 2020
Sponsor:
Collaborator:
Aferetica - Italy (BO)
Information provided by (Responsible Party):
Piero Luigi Ruggenenti, A.O. Ospedale Papa Giovanni XXIII

Brief Summary:

The 2019 outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID 19), which originated in Wuhan, China, has become a major concern all over the world.

Convalescent plasma or immunoglobulins have been used as a last resort to improve the survival rate of patients with SARS whose condition continued to deteriorate despite any attempted treatment.. Moreover, several studies showed a shorter hospital stay and lower mortality in patients treated with convalescent plasma than those who were not treated with convalescent plasma. Evidence shows that convalescent plasma from patients who have recovered from viral infections can be used effectively as a treatment of patients with active disease.

The use of solutions enriched of antiviral antibodies has several important advantages over the convalescent plasma including the high level of neutralizing antibodies supplied. Plasma-exchange is expensive and requires large volumes of substitution fluid. Albumin is better tolerated and less expensive, but exchanges using albumin solutions increase the risk of bleeding because of progressive coagulation factor depletion. With either albumin or fresh frozen plasma, increasing the risk of cardiovascular instability in the plasma donor and in the recipient, which can be detrimental in a critically ill patient with COVID 19 pneumonia.

The aforementioned limitations of plasma therapy can be overcome by using selective apheresis methods, such as double-filtration plasmapheresis (DFPP).DFPP is a modality of plasma purification that performs an initial plasma separation from blood, and the subsequent separation of specific molecules, on the basis of their specific molecular weight (cut-off), by using a fractionation filter. The Fractionation Filter 2A20, because of its membrane sieving cut-off, retains larger molecules and returns plasma along with smaller molecules to the circulation, including the major part of the albumin. The selection of the membrane 2A20 is related to the appropriate Sieving Coefficient for IgG that allows to efficiently collect antibodies from patients which are recovered from COVID-19, with negligible fluid losses and limited removal of albumin. The total amount of antibodies obtained during one DFPP session exceeds by three to four times the total amount provided to recipients with one unit of plasma obtained during one plasma-exchange session from one COVID-19 convalescent donor. This should result in more effective viral inhibition and larger benefit for the patient achieved with one unit of enriched immunoglobulin solution obtained with DFPP than with one unit of plasma obtained with plasma exchange.

These observations provide the background for a pilot study aimed to explore whether the infusion of antibodies obtained with one single DFPP procedure from voluntary convalescent donors could offer an effective and safe therapeutic option for critically ill patients with severe coronavirus (COVID-19) pneumonia requiring mechanical ventilation.


Condition or disease Intervention/treatment Phase
Pneumonia, Ventilator-Associated Coronavirus Infection Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)
Actual Study Start Date : April 15, 2020
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : August 2020


Arm Intervention/treatment
Experimental: Antibodies (immunoglobulins) infusion
Anti-coronavirus antibodies obtained with double-filtration plasmapheresis (DFPP )from convalescent patients.
Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients
Antibodies obtained from consenting convalescent donors will be administered to ten consecutive patients who fulfill the inclusion criteria . Convalescent antibodies will be obtained with one DFPP procedure from consenting donors and infused in one critically ill, ventilated patient with COVID 19 pneumonia.




Primary Outcome Measures :
  1. Number of mechanical ventilation days. [ Time Frame: Through study completion, an average of 6 months. ]

Secondary Outcome Measures :
  1. Survival [ Time Frame: Through study completion, an average of 6 months. ]
  2. Shift to Continuous Positive Airway Pressure (CPAP) ventilation [ Time Frame: Through study completion, an average of 6 months. ]
  3. Referral to a sub-intensive care unit or discharge [ Time Frame: Through study completion, an average of 6 months. ]
  4. Viral titer [ Time Frame: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months. ]
  5. Anti COVID 19 IgG antibodies [ Time Frame: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months. ]
  6. Anti COVID 19 IgM antibodies [ Time Frame: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months. ]
  7. C5a concentration [ Time Frame: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months. ]
    Marker of complement activation in plasma.

  8. C3a concentration [ Time Frame: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months. ]
    Marker of complement activation in plasma.

  9. Serum C5b-9 concentration [ Time Frame: Changes from before Ig administration, one day and one week after Ig administration and every week after discharge from the intensive care unit through study completion, an average of 6 months. ]
    Marker of complement activation in plasma.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Plasma Ig Donors

  • Adult (>18 and <65-yr-old) men and women
  • Convalescent donor who recovered from COVID 19 from at least 14 days according to the clinical and laboratory criteria defined by the Consiglio Superiore di Sanità on February 20, 2019 ("The recovered patient is the one who resolves the symptoms of COVID-19 infection and who is negative in two consecutive tests for the search for SARS-Cov-2, performed 24 hours apart") with the exceptions mentioned in the attached derogation (that is "no upper age limit to donation provided there are no clinical contraindications to the procedure and independent of documented evidence of two negative tests for SARS-Cov 2 naso-faringeal contamination")
  • Male or female donor; if female only if nulliparous; in both cases with a negative history of blood component transfusions
  • Careful clinical evaluation of the patient-donor with particular reference to the criteria established by current legislation to protect the health of the donor who donates by apheresis
  • Presence of adequate levels of neutralizing anti-SARS-COV-2 antibodies;
  • Biological qualification test negative defined by current indications (performed at SIMT of HPG23)
  • Test negative for: HAV RNA, HEV RNA, PVB19 DNA (performed at HPG23)
  • Informed consent

Recipients

  • Adult (>18-yr-old) men and women
  • COVID-19 pneumonia diagnosed by standard criteria
  • Need of ventilator support
  • Informed consent for participation in the study (critically ill patients will be unable to provide consent. Consent will be oral if a written consent will be impossible. If the subject is incapable of giving an informed consent and an authorized representative is not available without a delay that would, in the opinion of the Investigator, compromise the potential life-saving effect of the treatment this can be administered without consent. Consent to remain in the research should be sought as soon as the conditions of the patient will allow it).
  • <48 hours of mechanical ventilation

Exclusion Criteria:

  • >48 hour mechanical ventilation
  • Patient being treated with other anti-COVID-19 experimental treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04346589


Contacts
Layout table for location contacts
Contact: Piero Luigi Ruggenenti, MD 0039 035 267 ext 3814 pruggenenti@asst-pg23.it

Locations
Layout table for location information
Italy
IRFMN - Clinical Research Center for Rare Diseases Recruiting
Ranica, BG, Italy, 24020
Contact: Giuseppe Remuzzi, MD       giuseppe.remuzzi@marionegri.it   
Sub-Investigator: Marina Noris, Ch.         
Sub-Investigator: Miriam Galbusera, Biol.Sci. D.         
Sub-Investigator: Annalisa Perna, Stat.         
ASST HPG23 - Unit of Nephrology Recruiting
Bergamo, Italy, 24100
Contact: Piero Luigi Ruggenenti, MD    0039 035 267 ext 3341    pruggenenti@asst-pg23.it   
Sub-Investigator: Stefano Rota, MD         
Principal Investigator: Diego Curtò, MD         
ASST Papa Giovanni XXIII - Microbiology and Virology Unit Recruiting
Bergamo, Italy, 24100
Contact: Claudio Farina, MD       cfarina@asst-pg23.it   
Sub-Investigator: Annapaola Callegaro, MD         
Asst Pg23 - S.I.M.T Recruiting
Bergamo, Italy, 24100
Contact: Anna Falanga, MD       afalanga@asst-pg23.it   
Sub-Investigator: Luca Barcella, MD         
Sub-Investigator: Marina Marchetti, Biol. Sci.D.         
ASST-PG23 - Intensive Care Unit Recruiting
Bergamo, Italy, 24100
Contact: Ferdinando Luca Lorini, MD         
Sub-Investigator: Lorenzo Grazioli, MD         
Sponsors and Collaborators
A.O. Ospedale Papa Giovanni XXIII
Aferetica - Italy (BO)
Layout table for additonal information
Responsible Party: Piero Luigi Ruggenenti, Director, Unit of Nephrology, A.O. Ospedale Papa Giovanni XXIII
ClinicalTrials.gov Identifier: NCT04346589    
Other Study ID Numbers: DFPP COVID 19
First Posted: April 15, 2020    Key Record Dates
Last Update Posted: June 9, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Piero Luigi Ruggenenti, A.O. Ospedale Papa Giovanni XXIII:
Pneumonia COVID 19 ventilator-dependent
COVID19
Double-filtration plasmapheresis
Convalescent antibodies
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Coronavirus Infections
Severe Acute Respiratory Syndrome
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Cross Infection
Infection
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Immunologic Factors
Physiological Effects of Drugs